ROCKVILLE, Md., April 15 /PRNewswire-FirstCall/ -- Neuralstem, Inc. (Amex: CUR) today responds to an earlier press release by StemCells, Inc. by stating that StemCells, Inc. has completely mischaracterized the meaning of the US Patent and Trademark Office's most recent action.
"First," said Neuralstem President & CEO Richard Garr, "contrary to STEM's statement, the numerous substantial amendments made by STEM to get these two patents allowed completely destroy any basis for their assertions of infringement by Neuralstem.
"Second, I would like to remind everyone that the US Patent and Trademark Office upheld the patentability of Neuralstem's core technology in May, 2006, in response to a challenge from STEM. Our patents are not being challenged in this office action, nor in the suit which STEM brought against us.
"Finally, while we believe that any attempt by STEM to reopen their baseless law suit will be unsuccessful, as we asserted in our original response, Neuralstem does not infringe upon any of their "old" claims, nor do we infringe upon any of the significantly modified claims that they salvaged in the reexamination process."
Neuralstem's patented technology enables, for the first time, the ability to produce neural stem cells of the human brain and spinal cord in commercial quantities, and the ability to control the differentiation of these cells into mature, physiologically relevant human neurons and glia.
Major Central Nervous System diseases targeted by the Company with
research programs currently underway include: Is
|SOURCE Neuralstem, Inc.|
Copyright©2008 PR Newswire.
All rights reserved